---
slug: 'novo-nordisk-dcf-valuation'
date: '01/01/2025'
title: 'Novo Nordisk DCF Valuation: Should you invest in the Ozempic and Wegovy Maker for exeptional returns?'
subtitle: "Novo Nordisk was breifly Europe's largest company by market cap. Then it declined 60% less than 6 months later. A century-old pharmacheutical enterprise constantly innovating in it's specialization in blood-related illness and diabetes, Novo Nordisk is investing heavily in scaling their existing businesses. At the same time, NVO is investing exceptionally heavily in finding cure for new illnesses. NVO's online prescription delivery business and international revenue segmant is showing impressive growth. Let's analyze Novo Nordisk fundamental and conduct an intrinsic valuation of the company."
categories: ['NVO', 'Novo Nordisk', 'Denmark', 'DCF Valuation', 'Signals', 'Intrinsic Valuation']
image: 'https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-3vb55nukya4g1.png?width=1587&format=png&auto=webp&s=32fe1bd929e5fbe311dcbf87674cce898cbc366e'
author: 'Kanchan'
---

# Introduction

In this article, we conduct an intrinsic cash-flow valuation of Novo Nordisk, a leading bio and pharmacheutical company in the world. Danish Kroner is the currency throughout this valuation. This is not an investment advice. Stock investments are risky. Please consult your financial advisor before making any investment decisions.

# A Primer on Novo Nordisk : The Company

Novo Nordisk is Denmark's largest company by market cap, second largest by revenue. The company's stock has multiple listing,in home country Denmark as [Novo Nordisk B](https://www.nasdaq.com/european-market-activity/shares/novo-b?id=TX2178) and the NYSE as [NVO](https://www.nyse.com/quote/XNYS:NVO). Novo Nordisk breifly became the largest euopean company by market cap in 2024. Ever since, the company's stock has been on a freefall, having declined more than 60% since All-time-highs.

## Novo Nordisk Revenue Breakdown by Product Category

Novo Nordisk generated 290 Billion DKK in 2024 full-year revenue with YoY growth rate at 25%. Their revenue can be broken down into threee segments as such:

- Diabetes Care accounting for 71% of total revneue, 19% growth rate in 2024.
- Obesity Care accounting for 22% of total revneue, 56% growth rate in 2024.
- Rare Diasease accounting for 6.4% of total revneue, 9% growth rate in 2024.

![Novo Nordisk Revenue Breakdown By Product Category](https://preview.redd.it/an-intrinsic-discounted-cash-flow-valuation-of-novo-nordisk-v0-q73hvt7umf4g1.png?width=653&format=png&auto=webp&s=159b387fd756875e384bcb4d9e31ff16dbab94b7)

> Novo Nordisk is the world's largest producer of insulin, having produced [50% of global insuin supply](https://www.novonordisk.com/about/what-we-do.html) in 2022. Insulin sales revenue grew 15% year of year in 2024 to 55.3 Billion DKK in 2024, representing a 19% revenue segment for the company.

## Novo Nordisk Growth Story

Ozempic and Wegovy are Novo Nordisk's superhit drugs, accounting for

Novo Nordisk first received FDA approval for Ozempic (semaglutide) on December 5, 2017. At that time, it was simply approved as an add-on to diet and exercise to help adults with type 2 diabetes manage their blood sugar.

The real turning point came in January 2020, when the FDA expanded Ozempicâ€™s labelâ€”not for general diabetes use, but specifically to reduce major cardiovascular risks like heart attack, stroke, or cardiovascular-related death in people with type 2 diabetes who also had heart disease. This shifted Ozempicâ€™s story from just a diabetes drug to one that could also protect the heart, opening up a much larger clinical and commercial opportunity.

But the biggest change for Novo Nordisk happened in June 2021 with the FDA approval of Wegovy, a higher-dose version of semaglutide. Wegovy was approved specifically for chronic weight management in adults with obesity or those who were overweight. This marked Novo Nordiskâ€™s major entry into the booming obesity-care market and set the stage for the massive demand the company is seeing today.

# ðŸ“ˆ Novo Nordisk Revenue Shift: 2020 vs. 2024 by Major Segment and Geography (Sub-Row Format)

**All figures in DKK Millions (M DKK)**

| Segment / Product                     |   Year   | **Total Revenue (M DKK)** | **Int'l Revenue Portion (M DKK)** | **N. America Portion Revenue (M DKK)** | **% of Total Sales Combined** | **CAGR 2020-2024** |
| :------------------------------------ | :------: | :-----------------------: | :-------------------------------: | :------------------------------------: | :---------------------------: | :----------------: |
| **GLP-1 DIABETES**                    |          |                           |                                   |                                        |                               |                    |
| **RybelsusÂ®**                         | **2020** |           1,873           |                36                 |                 1,837                  |             1.5%              |     **84.3%**      |
|                                       | **2024** |          23,301           |              12,231               |                 11,070                 |             8.0%              |                    |
| **OzempicÂ®**                          | **2020** |          21,211           |               3,634               |                 17,577                 |             16.7%             |     **54.5%**      |
|                                       | **2024** |          120,342          |              29,055               |                 91,287                 |             41.4%             |                    |
| **VictozaÂ®**                          | **2020** |          18,747           |               7,095               |                 11,652                 |             14.8%             |       -27.8%       |
|                                       | **2024** |           5,482           |               3,686               |                 1,796                  |             1.9%              |                    |
| **GLP-1 OBESITY**                     |          |                           |                                   |                                        |                               |                    |
| **Obesity Care** (SaxendaÂ® & WegovyÂ®) | **2020** |           5,608           |               2,118               |                 3,490                  |             4.4%              |     **85.0%**      |
|                                       | **2024** |          65,146           |              16,988               |                 48,158                 |             22.4%             |                    |
| **TOTAL INSULIN**                     |          |                           |                                   |                                        |                               |                    |
| **Total Insulin**                     | **2020** |          56,550           |              38,352               |                 18,198                 |             44.5%             |       -0.5%        |
|                                       | **2024** |          55,373           |              38,978               |                 16,395                 |             19.1%             |                    |
| **RARE DISEASES**                     |          |                           |                                   |                                        |                               |                    |
| **Biopharm total** (Rare Diseases)    | **2020** |          18,926           |              11,648               |                 7,278                  |             14.9%             |       -0.4%        |
|                                       | **2024** |          18,639           |               9,437               |                 9,202                  |             6.4%              |                    |
| **TOTAL COMPANY REVENUE**             | **2020** |        **126,946**        |            **65,829**             |               **61,117**               |          **100.0%**           |     **22.8%**      |
|                                       | **2024** |        **290,403**        |            **112,231**            |              **178,172**               |          **100.0%**           |                    |
